Company intelligence / Profile preview

CoA Therapeutics

Palo Alto, California, United Statescoatherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

The lead compound targets PKAN by increasing activity across the PANK enzyme family to restore or boost cellular coenzyme A synthesis. The company’s approach has advanced into early clinical development with a focus on rare genetic disorders involving impaired energy metabolism. No published pivotal results yet. Pipeline includes additional programs for organic acidurias and other metabolic diseases.

Therapeutic areas: NeurologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BBP-671

Phase 1

Indications: Pantothenate kinase-associated neurodegeneration (PKAN), Propionic acidemia, Methylmalonic acidemia

Beyond the preview

Go deeper on CoA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoA Therapeutics.

Explore the full profile